$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cells 원문보기

Oncology letters, v.5 no.2, 2013년, pp.588 - 592  

KIM, KARAM (Molecular-Targeted Drug Research Center, Konkuk University, Gwangjin-gu, Seoul 143-701) ,  AN, SUNGKWAN ,  CHA, HWA JUN (Molecular-Targeted Drug Research Center, Konkuk University, Gwangjin-gu, Seoul 143-701) ,  CHOI, YEONG MIN ,  CHOI, SUNG JIN (Molecular-Targeted Drug Research Center, Konkuk University, Gwangjin-gu, Seoul 143-701) ,  AN, IN-SOOK ,  LEE, HONG GHI (Molecular-Targeted Drug Research Center, Konkuk University, Gwangjin-gu, Seoul 143-701) ,  MIN, YOO HONG ,  LEE, SU-JAE (Molecular-Targeted Drug Research Center, Konkuk University, Gwangjin-gu, Seoul 143-701) ,  BAE, SEUNGHEE

Abstract ▼ AI-Helper 아이콘AI-Helper

Non-small cell lung cancer (NSCLC) is the most deadly type of cancer worldwide. Although a number of therapies are used in NSCLC treatment, their therapeutic efficacy remains low. Lenalidomide was originally approved for use in patients with myelodysplastic syndromes, which are associated with 5q de...

주제어

#lenalidomide   #non-small cell lung carcinoma cell   #cell growth inhibition   #gene expression profiles  

참고문헌 (26)

  1. 1. Ferlay J Shin HR Bray F GLOBOCAN 2008, Cancer incidence and mortality worldwide IARC CancerBase No. 10 Lyon, France International Agency for Research on Cancer 2010 http://globocan.iarc.fr 

  2. 2. American Cancer Society 2010 Cancer facts and figures Atlanta, GA American Cancer Society 2010 

  3. 3. Herbst RS Heymach JV Lippman SM Lung cancer N Engl J Med 359 1367 1380 2008 18815398 

    상세보기

  4. 4. List A Kurtin S Roe DJ Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 549 557 2005 15703420 

    상세보기

  5. 5. Hideshima T Richardson PG Anderson KC Current therapeutic uses of lenalidomide in multiple myeloma Expert Opin Investig Drugs 15 171 179 2006 

  6. 6. Eisen T Trefzer U Hamilton A Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma Cancer 116 146 154 2010 19862820 

  7. 7. Kalmadi S Davis M Dowlati A Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors Invest New Drugs 25 211 216 2007 17103043 

  8. 8. Miller AA Case D Harmon M Phase I study of lenalidomide in solid tumors J Thorac Oncol 2 445 449 2007 17473661 

    상세보기

  9. 9. Dahut WL Aragon-Ching JB Woo S Phase I study of oral lenalidomide in patients with refractory metastatic cancer J Clin Pharmacol 49 650 660 2009 19451403 

    상세보기

  10. 10. Bartlett JB Tozer A Stirling D Zeldis JB Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide Br J Cancer 93 613 619 2005 16222306 

  11. 11. Tohnya TM Ng SS Dahut WL A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer Clin Prostate Cancer 2 241 243 2004 15072608 

  12. 12. Gupta D Treon SP Shima Y Adherence of multiple myeloma cells to bone marrow stromal cells up-regulates vascular endothelial growth factor secretion: therapeutic applications Leukemia 15 1950 1961 2001 11753617 

    상세보기

  13. 13. Teo SK Properties of thalidomide and its analogues: implications for anticancer therapy AAPS J 7 E14 E19 2005 16146335 

  14. 14. Corral LG Haslett PA Muller GW Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha J Immunol 163 380 386 1999 10384139 

  15. 15. Dredge K Marriott JB Todryk SM Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity J Immunol 168 4914 4919 2002 11994441 

    상세보기

  16. 16. Bartlett JB Dredge K Dalgleish AG The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat Rev Cancer 4 314 322 2004 15057291 

  17. 17. Verhelle D Corral LG Wong K Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells Cancer Res 67 746 755 2007 17234786 

    상세보기

  18. 18. Kotla V Goel S Nischal S Mechanism of action of lenalidomide in hematological malignancies J Hematol Oncol 2 36 2009 19674465 

    상세보기

  19. 19. Li S Pal R Monaghan SA IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM Blood 117 5157 5165 2011 21389327 

  20. 20. Lopez-Girona A Heintel D Zhang LH Lenalidomide down-regulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response Br J Haematol 154 325 336 2011 21707574 

    상세보기

  21. 21. Puthalakath H Strasser A Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins Cell Death Differ 9 505 512 2002 11973609 

    상세보기

  22. 22. Durchdewald M Angel P Hess J The transcription factor Fos: a Janus-type regulator in health and disease Histol Histopathol 24 1451 1461 2009 19760594 

  23. 23. Chhieng DC Cangiarella JF Zakowski MF Goswami S Cohen JM Yee HT Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens Cancer 93 330 336 2001 11668468 

  24. 24. Tanaka H Yanagisawa K Shinjo K Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1 Cancer Res 67 6007 6011 2007 17616654 

    상세보기

  25. 25. Kwei KA Kim YH Girard L Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer Oncogene 27 3635 3640 2008 18212743 

    상세보기

  26. 26. Winslow MM Dayton TL Verhaak RG Suppression of lung adenocarcinoma progression by Nkx2-1 Nature 473 101 104 2011 21471965 

    상세보기
LOADING...

관련 콘텐츠

오픈액세스(OA) 유형

GOLD

오픈액세스 학술지에 출판된 논문

이 논문과 함께 이용한 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로